Oncorus to Present at Upcoming Investor Conferences
November 23 2021 - 7:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced that President and Chief Executive
Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in
two upcoming virtual investor conferences:
- 33rd Annual Piper
Sandler Virtual Healthcare Conference: A corporate
presentation will be available on-demand starting Monday, November
22nd at 10:00 a.m. ET.
- Evercore ISI 4th Annual
HealthCONx Conference: Fireside chat on Wednesday,
December 1st, 2021 at 4:45 p.m. ET.
A webcast of each conference presentation will be
available under the Investors & Media section of Oncorus’
website at https://investors.oncorus.com/. A replay of the
presentations will be archived on Oncorus’ site for 30 days
following the event.
About OncorusAt Oncorus, we are
focused on driving innovation to deliver next-generation viral
immunotherapies to transform outcomes for cancer patients. We are
advancing a portfolio of intratumorally (iTu) and intravenously
(IV) administered viral immunotherapies for multiple indications
with significant unmet need based on our oncolytic Herpes Simplex
Virus (HSV) Platform and Synthetic viral RNA (vRNA) Immunotherapy
Platform.
Designed to deliver next-generation viral
immunotherapy impact, our HSV Platform improves upon key
characteristics of this therapeutic class to enhance systemic
activity. Our lead HSV program, ONCR-177, is designed to be
directly administered into a tumor, resulting in high local
concentrations of the therapeutic agent and its five encoded
transgenes, as well as low systemic exposure to the therapy, which
could limit systemic toxicities. Our pioneering Synthetic vRNA
Immunotherapy Platform involves a highly innovative, novel
combination of RNA- and oncolytic virus-based modalities designed
to realize the potential of RNA medicines for cancer. Our lead
IV-administered Synthetic vRNA Immunotherapy clinical candidates,
ONCR-021 and ONCR-788, are both currently in IND-enabling
studies.
Please visit www.oncorus.com to learn more.
Media
Contact: Liz
Meloneliz@scientpr.com Investor
Contact:Stern Investor Relations Julie
SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024